keyword
MENU ▼
Read by QxMD icon Read
search

adjuvant treatment breast cancer

keyword
https://www.readbyqxmd.com/read/29048991/impacts-of-early-guideline-directed-21-gene-recurrence-score-testing-on-adjuvant-therapy-decision-making
#1
Hannah Dzimitrowicz, Sarah Mougalian, Sherri Storms, Sandra Hurd, Anees B Chagpar, Brigid K Killelea, Nina R Horowitz, Donald R Lannin, Malini Harigopal, Erin Hofstatter, Michael P DiGiovanna, Kerin B Adelson, Andrea Silber, Maysa Abu-Khalaf, Gina Chung, Wajih Zaheer, Osama Abdelghany, Christos Hatzis, Lajos Pusztai, Tara B Sanft
PURPOSE: The 21-gene recurrence score (RS) assay is used to help formulate adjuvant chemotherapy recommendations for patients with estrogen receptor-positive, early-stage breast cancer. Most frequently, medical oncologists order RS after surgery. Results take an additional 2 weeks to return, which can delay decision making. We conducted a prospective quality-improvement project to assess the impact of early guideline-directed RS ordering by surgeons before the first visit with a medical oncologist on adjuvant therapy decision making...
October 19, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29047418/primary-small-cell-carcinoma-of-the-breast-a-case-report
#2
Iman Abou Dalle, Jaber Abbas, Fouad Boulos, Ziad Salem, Hazem I Assi
BACKGROUND: Neuroendocrine breast cancer is a rare entity that was defined in 2003 by the World Health Organization as a separate breast cancer subtype. The diagnosis of neuroendocrine breast cancer requires the presence of neuroendocrine features in at least 50% of malignant cells, the exclusion of non-mammary primary tumors, as well as the presence of an in situ component in breast histology. The treatment and prognosis of neuroendocrine breast cancer are still not well established...
October 19, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29045642/patient-and-tumor-characteristics-and-their-influence-on-early-therapy-persistence-with-letrozole-in-postmenopausal-patients-with-early-breast-cancer
#3
N Nabieva, S Kellner, T Fehm, L Häberle, J de Waal, M Rezai, B Baier, G Baake, H-C Kolberg, M Guggenberger, M Warm, N Harbeck, R Wuerstlein, J-U Deuker, P Dall, B Richter, G Wachsmann, C Brucker, J W Siebers, N Fersis, T Kuhn, C Wolf, H-W Vollert, G-P Breitbach, W Janni, R Landthaler, A Kohls, D Rezek, T Noesselt, G Fischer, S Henschen, T Praetz, V Heyl, T Kühn, T Krauss, C Thomssen, A Hohn, H Tesch, C Mundhenke, A Hein, C Rauh, C M Bayer, A Jacob, K Schmidt, E Belleville, S Y Brucker, S Kümmel, M W Beckmann, D Wallwiener, P Hadji, P A Fasching
Background: Patients' compliance and persistence with endocrine treatment has a significant effect on the prognosis in early breast cancer (EBC). The purpose of this analysis was to identify possible reasons for non-persistence, defined as premature cessation of therapy, on the basis of patient and tumor characteristics in individuals receiving adjuvant treatment with letrozole. Patients and methods: The EvAluate-TM Study is a prospective, multicenter, noninterventional study in which treatment with the aromatase inhibitor letrozole was evaluated in postmenopausal women with hormone receptor-positive EBC in the early therapy phase...
October 10, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045452/prospective-multicenter-french-study-evaluating-the-clinical-impact-of-the-breast-cancer-intrinsic-subtype-prosigna%C3%A2-test-in-the-management-of-early-stage-breast-cancers
#4
Delphine Hequet, Céline Callens, David Gentien, Benoit Albaud, Marie-Ange Mouret-Reynier, Coraline Dubot, Paul Cottu, Cyrille Huchon, Sonia Zilberman, Helene Berseneff, Cyril Foa, Rémy Salmon, Aurélie Roulot, Florence Lerebours, Anne Salomon, Nadeem Ghali, Pascale Morel, Qianyi Li, Anne Cayre, Jean-Marc Guinebretière, John Hornberger, Frédérique Penault-Llorca, Roman Rouzier
PURPOSE: The Prosigna® breast cancer prognostic gene signature assay identifies a gene-expression profile that permits the classification of tumors into subtypes and gives a score for the risk of recurrence (ROR) at 10 years. The primary objective of this multicenter study was to evaluate the impact of Prosigna's assay information on physicians' adjuvant treatment decisions in patients with early-stage breast cancer. Secondary objectives were to assess confidence of practitioners in their therapeutic recommendations before and after the added information provided by the Prosigna assay; and to evaluate the emotional state of patients before and after the Prosigna test results...
2017: PloS One
https://www.readbyqxmd.com/read/29045014/efficacy-and-toxicity-of-pegylated-liposomal-doxorubicin-based-chemotherapy-in-early-stage-breast-cancer-a-multicenter-retrospective-case-control-study
#5
Fu Ou Yang, Nicholas C Hsu, Sin-Hua Moi, Yin-Che Lu, Chia-Ming Hsieh, King-Jen Chang, Dar-Ren Chen, Chi-Wen Tu, Hwei-Chung Wang, Ming-Feng Hou
AIM: PEGylated liposomal doxorubicin (PLD) has comparable efficacy and differing toxicity from conventional anthracyclines used to treat advanced breast cancer. This study compared disease-free survival and toxicity between PLD-based and conventional anthracycline-based regimens as adjuvant treatments for early-stage breast cancer. METHODS: We analyzed disease-free survival (DFS) rates, and adverse events in 102 women with early-stage (I-IIIa) breast cancer who received adjuvant PLD-based chemotherapy from 2002 to 2008...
October 18, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29039550/autophagy-is-essential-for-flavopiridol%C3%A2-induced-cytotoxicity-against-mcf%C3%A2-7-breast-cancer-cells
#6
Shuo Wang, Kai Wang, Huaiquan Wang, Jiankui Han, Hukui Sun
Flavopiridol (FP) exerts antitumoral effects by triggering tumor cell cycle arrest and cytotoxicity in human breast cancer cell lines. The potent antitumor activity of FP is through its inhibition of cyclin‑dependent kinases; however, this may not be the only mechanism of action. The present study aimed to investigate whether FP is able to induce autophagy and to examine the effects of autophagy on cell death in FP‑treated MCF‑7 human breast cancer cells. MCF‑7 cells were treated with either FP alone or FP in combination with chloroquine (CQ)...
October 17, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29037984/effect-of-maf-amplification-on-treatment-outcomes-with-adjuvant-zoledronic-acid-in-early-breast-cancer-a-secondary-analysis-of-the-international-open-label-randomised-controlled-phase-3-azure-big-01-04-trial
#7
Robert Coleman, Andrew Hall, Joan Albanell, Andrew Hanby, Richard Bell, David Cameron, David Dodwell, Helen Marshall, Joël Jean-Mairet, Juan-Carlos Tercero, Federico Rojo, Walter Gregory, Roger R Gomis
BACKGROUND: Adjuvant use of bisphosphonates can reduce the incidence of bone metastases in early breast cancer. Recurrence and survival seem to be improved only in postmenopausal patients, but the underlying mechanisms remain unclear. We investigated whether MAF amplification (a biomarker for bone metastasis) in primary tumours could predict the treatment outcomes of adjuvant zoledronic acid. METHODS: The study population included patients enrolled in the international, open-label, randomised, controlled, phase 3 AZURE trial at eligible UK sites who had stage II or III breast cancer and who gave consent for use of their primary tumour samples...
October 13, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29037213/personalized-treatment-of-women-with-early-breast-cancer-a-risk-group-specific-cost-effectiveness-analysis-of-adjuvant-chemotherapy-accounting-for-companion-prognostic-tests-oncotypedx-and-adjuvant-online
#8
Beate Jahn, Ursula Rochau, Christina Kurzthaler, Michael Hubalek, Rebecca Miksad, Gaby Sroczynski, Mike Paulden, Marvin Bundo, David Stenehjem, Diana Brixner, Murray Krahn, Uwe Siebert
BACKGROUND: Due to high survival rates and the relatively small benefit of adjuvant therapy, the application of personalized medicine (PM) through risk stratification is particularly beneficial in early breast cancer (BC) to avoid unnecessary harms from treatment. The new 21-gene assay (OncotypeDX, ODX) is a promising prognostic score for risk stratification that can be applied in conjunction with Adjuvant!Online (AO) to guide personalized chemotherapy decisions for early BC patients...
October 16, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29035298/molecular-docking-and-3d-pharmacophore-modeling-to-study-the-interactions-of-chalcone-derivatives-with-estrogen-receptor-alpha
#9
Muchtaridi Muchtaridi, Hasna Nur Syahidah, Anas Subarnas, Muhammad Yusuf, Sharon D Bryant, Thierry Langer
Tamoxifen is the most frequently used anti-estrogen adjuvant treatment for estrogen receptor-positive breast cancer. However, it is associated with an increased risk of several serious side-effects, such as uterine cancer, stroke, and pulmonary embolism. The 2',4'-dihydroxy-6-methoxy-3,5-dimethylchalcone (ChalcEA) from plant leaves of Eugenia aquea, has been found to inhibit the proliferation of MCF-7 human breast cancer cells in a dose-dependent manner, with an IC50 of 74.5 μg/mL (250 μM). The aim of this work was to study the molecular interactions of new ChalcEA derivatives formed with the Estrogen Receptor α (ERα) using computer aided drug design approaches...
October 16, 2017: Pharmaceuticals
https://www.readbyqxmd.com/read/29034804/cip2a-expression-predicts-recurrences-of-tamoxifen-treated-breast-cancer
#10
Shawn Baldacchino, Laura M Wastall, Christian Saliba, Thomas A Hughes, Christian Scerri, Angelene Berwick, Valerie Speirs, Andrew M Hanby, Godfrey Grech
CIP2A is emerging as an oncoprotein overexpressed commonly across many tumours and generally correlated with higher tumour grade and therapeutic resistance. CIP2A drives an oncogenic potential through inhibiting protein phosphatase 2A, stabilizing MYC, and promoting epithelial-to-mesenchymal transition, although further biological mechanisms for CIP2A are yet to be defined. CIP2A protein expression was studied by immunohistochemistry in oestrogen receptor-positive primary breast cancers (n = 250) obtained from the Leeds Tissue Bank...
October 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/29031778/extended-adjuvant-aromatase-inhibition-after-sequential-endocrine-therapy-data-a-randomised-phase-3-trial
#11
Vivianne C G Tjan-Heijnen, Irene E G van Hellemond, Petronella G M Peer, Astrid C P Swinkels, Carolien H Smorenburg, Maurice J C van der Sangen, Judith R Kroep, Hiltje De Graaf, Aafke H Honkoop, Frans L G Erdkamp, Franchette W P J van den Berkmortel, Maaike de Boer, Wilfred K de Roos, Sabine C Linn, Alexander L T Imholz, Caroline M Seynaeve
BACKGROUND: The effect of extended adjuvant aromatase inhibition in hormone receptor-positive breast cancer after sequential endocrine therapy of tamoxifen followed by an aromatase inhibitor for a 5-year treatment period still needs clarification. To address this issue, we began the DATA study to assess different durations of anastrozole therapy after tamoxifen. METHODS: DATA was a prospective, randomised, open-label, multicentre, phase 3 study done in 79 hospitals in the Netherlands...
October 11, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29031423/the-state-of-surgical-axillary-management-and-adjuvant-radiotherapy-for-early-stage-invasive-breast-cancer-in-the-modern-era
#12
Justin M Mann, Xian Wu, Paul Christos, Himanshu Nagar
BACKGROUND: For clinical T1-2N0 breast cancer, sentinel lymph node biopsy (SLNB) has been shown in American College of Surgeons Oncology Group (ACOSOG) Z0011 to be sufficient for women with 1 to 2 positive sentinel lymph nodes with no added benefit for completion axillary lymph node dissection (ALND). Z0011 specified whole breast radiotherapy (RT) using standard tangential fields; however, later analysis showed variation in field design. We assessed nationwide practice patterns and examined factors associated with patients undergoing completion ALND and subsequent radiation field design...
September 19, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29031034/-potential-of-using-vitamin-d-as-an-adjuvant-treatment-of-malignant-melanoma
#13
B Bolerázska, E Ďurovcová, M Mareková
The incidence of malignant melanoma worldwide continues to grow despite the enormous advances in topical and systemic therapy. This increase is recorded regularly even in countries where, as a result of public health campaigns, dermatological examination and subsequent treatment have become more frequent. However, there have been reports of a stable or even decreasing mortality rate that seem to contradict the objective increase in its incidence. The well-known risk factors for malignant melanoma include sunburns and occasional sunbathing, whereas regular sunbathing is associated with a lower incidence...
2017: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/29030786/routine-treatment-and-outcome-of-breast-cancer-in-younger-versus-elderly-patients-results-from-the-senora-project-of-the-prospective-german-tmk-cohort-study
#14
Thomas Fietz, Mark-Oliver Zahn, Andreas Köhler, Erik Engel, Melanie Frank, Lisa Kruggel, Martina Jänicke, Norbert Marschner
PURPOSE: There is an ongoing discussion about 'undertreatment' of breast cancer in elderly patients. Due to low accrual into clinical trials, level 1 evidence is scarce. We report prospective data of elderly patients with breast cancer treated by medical oncologists in Germany. METHODS: The SENORA project within the prospective cohort study TMK (Tumour Registry Breast Cancer) was conducted in 82 centres from 2007-2015. Among 2316 patients, half were enrolled with curative and half with palliative treatment intention...
October 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29025611/carbon-fiber-reinforced-intramedullary-nailing-in-musculoskeletal-tumor-surgery-a-national-multicentric-experience-of-the-italian-orthopaedic-society-siot-bone-metastasis-study-group
#15
Andrea Piccioli, Raimondo Piana, Michele Lisanti, Alberto Di Martino, Barbara Rossi, Francesco Camnasio, Marco Gatti, Pietro Maniscalco, Franco Gherlinzoni, Maria Silvia Spinelli, Davide Maria Donati, Roberto Biagini, Rodolfo Capanna, Vincenzo Denaro
INTRODUCTION: Carbon fiber reinforced (CFR) implants have been proposed for the treatment of fractures or impending fractures of the long bones in the oncology patient. Aim of this study is to present the largest cohort of oncology patients operated by CFR nailing by the Italian Orthopaedic Society (SIOT) Bone Metastasis Study Group. METHODS: 53 adult oncology patients were operated on with a CFR-PEEK nail. All the data from adjuvants therapies were collected. Bone callus formation, response to radiotherapy, relapse or progression of the osteolysis were recorded...
October 2017: Injury
https://www.readbyqxmd.com/read/29022483/in-vitro-combined-effect-of-doxorubicin-and-sulfonated-zinc-phthalocyanine-mediated-photodynamic-therapy-on-mcf-7-breast-cancer-cells
#16
Eric Chekwube Aniogo, Blassan Plackal Adimuriyil George, Heidi Abrahamse
Doxorubicin is a broad-spectrum antibiotic and anticancer drug used to treat a variety of human malignancies like breast cancer and leukaemia. Unfortunately, a dose-dependent side effect of this drug is common, representing a major obstacle to its use despite its therapeutic efficacy. Photodynamic therapy is an emerging non-invasive potential adjuvant for conventional cancer treatment. In an attempt to circumvent the dose-limiting effect of doxorubicin, this study aimed to investigate cellular anticancer activity of doxorubicin and sulfonated zinc phthalocyanine-mediated photodynamic therapy on MCF-7 cells alone and in combination...
October 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28991038/exercise-prescription-and-adherence-for-breast-cancer-one-size-does-not-fitt-all
#17
Amy A Kirkham, Alis Bonsignore, Kelcey A Bland, Donald C McKenzie, Karen A Gelmon, Cheri L Van Patten, Kristin L Campbell
PURPOSE: To prospectively assess adherence to oncologist-referred, exercise programming consistent with current recommendations for cancer survivors among women with early breast cancer across the trajectory of adjuvant treatment. METHODS: Sixty-eight women participated in supervised, hour-long, moderate-intensity, aerobic and resistance exercise 3x/week during adjuvant chemotherapy ± radiation, with a step-down in frequency for 20 additional weeks. Adherence to exercise frequency (i...
October 5, 2017: Medicine and Science in Sports and Exercise
https://www.readbyqxmd.com/read/28990127/patterns-of-axillary-evaluation-in-older-patients-with-breast-cancer-and-associations-with-adjuvant-therapy-receipt
#18
Laura S Dominici, Helmneh M Sineshaw, Ahmedin Jemal, Chun Chieh Lin, Tari A King, Rachel A Freedman
PURPOSE: Although axillary lymph node status has traditionally been a key factor in informing adjuvant breast cancer therapy recommendations, this information may be less relevant as our focus shifts more towards tumor biology, particularly in older patients where comorbidity influences treatment decisions and nodal staging and/or surgery may not improve outcomes. We examined patterns of axillary surgery and associations between axillary surgery and receipt of adjuvant treatment in older breast cancer patients...
October 9, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28989000/use-of-18-f-fdg-pet-ct-imaging-to-determine-internal-mammary-lymph-node-location-for-radiation-therapy-treatment-planning-in-breast-cancer-patients
#19
Tima Davidson, Merav Ben-David, Shira Galper, Tess Haskin, Megan Howes, Roland Scaife, Nayroz Kanana, Uri Amit, Noam Weizman, Bar Chikman, Elinor Goshen, Simona Ben-Haim, Zvi Symon, Jeffrey Goldstein
PURPOSE: Adjuvant internal mammary lymph node (IMN) radiation is often delivered with 2-dimensional techniques that use anatomic landmarks and predetermined depths for field placement and dose specification. In contrast, 3-dimensional planning uses the internal mammary vessels (IMVs) to localize the IMNs for planning. Our purpose was to determine if localization of the involved IMN (i-IMN) by (18)F-labeled fluorodeoxyglucose positron emission tomography-computed tomography ((18)F-FDG PET-CT) offers opportunities to improve treatment...
November 5, 2016: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28986743/monosomy-17-in-potentially-curable-her2-amplified-breast-cancer-prognostic-and-predictive-impact
#20
David B Page, Hannah Wen, Edi Brogi, Dana Dure, Dara Ross, Kateri J Spinelli, Sujata Patil, Larry Norton, Clifford Hudis, Heather L McArthur
PURPOSE: HER2 copy number by fluorescence in situ hybridization (FISH) is typically reported relative to the centromere enumeration probe 17 (CEP17). HER2/CEP17 ratio could be impacted by alterations in the number of chromosome 17 copies. Monosomy of chromosome 17 (m17) is found in ~ 1900 cases of early-stage HER2-positive breast cancer annually in the United States; however, the efficacy of HER2-directed trastuzumab therapy in these patients is not well characterized. Here, we retrospectively identified HER2-amplified, stage I-III breast cancers with m17 and characterized the impact of trastuzumab treatment...
October 6, 2017: Breast Cancer Research and Treatment
keyword
keyword
116441
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"